SEC Tracker
Get the app
ARMP · XBRL financial data

Armata Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ARMP's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026†Jun 30, 2026
General and administrative3,5833,179*3,1783,4393,2443,323*3,2532,6193,1113,426*3,4635,236
Total operating expenses11,56111,107*11,19411,91412,72911,774*8,6829,0138,93514,908*9,57412,822
Operating income (loss)(10,336)(9,579)*(10,228)(11,914)(9,756)(10,539)*(8,191)(6,844)(7,776)(13,823)*(8,785)(10,312)
Interest income4768*52221————————
Interest expense1,1761,450*1,8202,718————————
Other income (expense)(20,825)(10,268)*(14,793)20,9004,27513,139*1,660(9,451)(18,899)(110,475)*(106,561)84,453
Income tax expense (benefit)0—000—00*0—00*
Net income (loss)(31,161)(19,847)*(25,021)8,986(5,481)2,600*(6,531)(16,295)(26,675)(124,298)*(115,346)74,141
Earnings per share, basic USD per share(0.86)(0.55)*(0.69)0.25(0.15)0.07*(0.18)(0.45)(0.74)(3.42)*(3.16)2.02
Earnings per share, diluted USD per share(0.86)—(0.69)(0.25)(0.15)—(0.20)(0.45)(0.74)—(3.16)(0.27)
Weighted average shares, basic thousands of shares36,08736,101*36,12536,15536,18036,183*36,18536,19336,22636,351*36,53036,748
Weighted average shares, diluted thousands of shares36,087—36,12558,24736,180—59,47936,19336,226—36,53062,042
  • † Share count changed about 1/998 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1013x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (ARMP's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026†Jun 30, 2026
Cash and cash equivalents23,95813,52337,86026,40517,1419,29111,6884,32814,7568,6884,75423,952
Prepaid and other current assets—2,2652,1433,2563,0291,2731,2401,0241,4151,5081,145673
Total current assets36,58519,15141,71730,90322,38911,30813,1667,52016,93010,6685,94627,157
Property and equipment, net9,25012,55912,70013,47413,61613,24112,88312,65712,56012,19411,78011,230
Right-of-use asset44,88644,71744,24343,67142,25141,68741,09040,50439,91733,91133,39532,884
Goodwill3,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,4903,490
Total assets112,76198,363120,356108,31398,23786,43787,25080,79089,51676,88269,80089,950
Accounts payable3,7721,5852,0571,7431,8157669819651,2809216601,193
Total current liabilities21,88416,461110,045123,181118,20448,249110,540120,085139,9508,9479,228250,199
Lease liability, non-current28,16228,58328,37628,15627,92927,69427,41627,13126,83726,53326,18325,823
Total liabilities125,147130,428176,866154,414149,210134,456141,033150,293185,104295,478381,386321,123
Accumulated deficit(288,972)(308,819)(333,840)(324,854)(330,335)(327,735)(334,266)(350,561)(377,236)(501,534)(616,880)(542,739)
Total stockholders' equity(12,386)(32,065)(56,510)(46,101)(50,973)(48,019)(53,783)(69,503)(95,588)(218,596)(311,586)(231,173)
Total liabilities and equity112,76198,363120,356108,31398,23786,43787,25080,79089,51676,88269,80089,950
Common shares outstanding (cover page) thousands of shares36,14736,14936,15536,18336,18336,18336,19336,23036,33036,6333737,182
  • † Share count changed about 1/998 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1013x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (ARMP's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026†Jun 30, 2026
Net income (loss)(31,161)(19,847)*(25,021)8,986(5,481)2,600*(6,531)(16,295)(26,675)(124,298)*(115,346)74,141
Stock-based compensation(373)*193*5341,335*670*354*781575*622*632*1,0753,391*
Depreciation and amortization221*293*317315*313*380*377366*370*———
Net cash from operating activities(9,687)*(8,106)*(10,584)(10,177)*(8,863)*(7,927)*(7,580)(7,211)*(4,298)*(6,674)*(5,782)(8,666)*
Purchases of property and equipment3,512*2,400*2501,366*340*(77)*99149*242*52*6317*
Net cash from investing activities(3,512)*(2,390)*(250)(1,366)*(340)*77*(99)(149)*(242)*(52)*(63)(17)*
Net cash from financing activities24,805*(43)*34,93188*(61)*0*9,9860*14,968*658*64127,881*
Net change in cash11,606*(10,539)*24,097(11,455)*(9,264)*(7,850)*2,307(7,360)*10,428*(6,068)*(5,204)19,198*
  • † Share count changed about 1/998 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1013x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Armata Pharmaceuticals23,952not reported(8,666)*37.2M2.8 quarters 10-QJun 30, 2026
Imunon6,864not reported(3,025)*5.6M2.3 quarters 10-QJun 30, 2026
Fibrogen50,644(1,474)(3,991)*4.0M22.9 quarters 10-QJun 30, 2026
Lunai Bioworks1,71431*(1,841)*5.0M0.9 quarters 10-KJun 30, 2026
Dare Bioscience12,618188(6,775)*15.3M1.9 quarters 10-QJun 30, 2026
Aptose Biosciences1,020not reported(5,841)2.6M0.2 quarters 10-QMar 31, 2026
Ovid Therapeutics11,327733(17,594)*195.3M6.7 quarters 10-QJun 30, 2026
vTv Therapeutics86,6430(11,443)*not reported7.6 quarters 10-QJun 30, 2026
Marimed8,43741,9252,219*403.0M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.